BMO Capital Reiterates Outperform Rating on Structure Therapeutics (GPCR)

BMO Capital analyst Evan Seigerman reiterated an Outperform rating and $100.00 price target on Structure Therapeutics (NASDAQ: GPCR).

The analyst comments "Structure shares have been under pressure (-24% since 6/3) following a positive reaction to the company's Ph 2a data in obese patients (note here); shares have given back nearly all of the gains (closing $34.20 on 5/31). We believe this move, largely driven by profit taking and capitulation on a buyout opportunity, is overdone with Structure's Ph 2a data a clear win. The data demonstrating competitive placeboadjusted weight loss of 6.2% at 12 weeks and an AE profile manageable through dose titration, clearing the path for its Ph 2b trial."

For an analyst ratings summary and ratings history on Structure Therapeutics click here. For more ratings news on Structure Therapeutics click here.

Shares of Structure Therapeutics closed at $39.96 yesterday.

You May Also Be Interested In